Antimalarial Efficacy of a Quantified Extract of Nauclea pobeguinii Stem Bark in Human Adult Volunteers with Diagnosed Uncomplicated Falciparum Malaria. Part 1: A Clinical Phase IIA Trial

Abstract

The aim of this phase IIA clinical trial was to assess the efficacy of an 80 % ethanolic quantified extract (containing 5.6 % strictosamide as the putative active constituent) from Nauclea pobeguinii stem bark denoted as PR 259 CT1 in a small group of adult patients diagnosed with uncomplicated falciparum malaria. Results obtained from a phase I clinical trial on healthy male volunteers indicated that the oral administration during meals of two 500 mg capsules three times daily (each eight hours) during seven days was well tolerated and showed only mild and self-resolving adverse effects. This PR 259 CT1 drug regimen was obtained by mathematical conversion of animal doses obtained in several in vivo studies in mice to human equivalent doses as in falciparum malaria patients. The phase IIA study was an open cohort study in eleven appraisable adult patients suffering from proven Plasmodium falciparum malaria. The study was specifically designed to assess the efficacy of PR 259 CT1 administered with a dose regimen of two 500 mg capsules three times daily for three days, followed by outpatient treatment of one 500 mg capsule three times daily for the next four days, in order to prove that this therapeutic dose, which was calculated from animal doses, was effective to treat adult malaria patients and consequently useful for a future Phase IIB clinical trial. This study would then substitute a dose-escalating trial, which in general is used to find the appropriate dose for clinical studies. The phase IIA clinical trial was carried out according to the WHO 2003 14-day test, and the results revealed that all eleven patients were completely cleared of parasitemia and fever on days 3, 7, and 14 except for one patient, who experienced a recurrence of parasitemia at days 7 until 14. Besides this adequate clinical and parasitological response (ACPR), this trial also demonstrated that PR 259 CT1 was well tolerated with only mild and self-resolving adverse effects including fatigue and headache, which were in accordance with those found in the phase I clinical trial. Moreover, all symptoms progressively disappeared, and no symptoms were observed on day 14. Although the number of patients included in this study was rather limited, the statistical analysis nevertheless suggested the efficacy and tolerability of PR 259 CT1, which indicated that this herbal medicinal product might be considered as a putative candidate for a large scale clinical trial.

Key words

Nauclea pobeguinii - Rubiaceae - malaria - Plasmodium falciparum - strictosamide - herbal medicine - traditional medicine

References

• 1 American Cancer Society .Clinical trials: What you need to know. Available at http://www.cancer.org/docroot/ETO Last accessed March 17, 2010
• 2 Dhooghe L, Mesia K, Kohtala E, Tona L, Pieters L, Vlietinck A J. Development and validation of an HPLC-method for the determination of alkaloids in the stem bark extract of Nauclea pobeguinii.  Talanta. 2008;  15 462-468
• 3 Mesia K G, Cimanga K R, Dhooghe L, Cos P, Apers S, Totté J, Tona L G, Pieters L, Vlietinck A J, Maes L. Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract.  J Ethnopharmacol. 2010;  131 10-16
• 4 Mesia K, Cimanga K, Tona L, Mampunza M M, Ntamabyaliro N, Muanda T, Muyembe T, Totté J, Pieters L, Vlietinck A. Assessment of the short-term safety and tolerability of a quantified 80 % ethanol extract from the stem bark of Nauclea pobeguinii (PR 259 CT1) in healthy volunteers: a clinical phase I study.  Planta Med. 2011;  77 111-116
• 5 US Department of Health and Human Services, Food and Drug Administration .Guidance for industry, investigators, and reviewers – Exploratory IND studies. Geneva: WHO; 2006. (Available at http://www.fda.gov/downloads/Drugs/Guidance%20ComplianceRegulatoryInformation/Guidances/ucm078933.pdf Last accessed March 17, 2010)
• 6 WHO .Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003 Geneva: WHO; 2003: 1-68
• 7 WHO .Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Adapted from “The use of essential drugs, 8th list”. WHO Technical Report Series, No. 850 Geneva: WHO; 1995
• 8 Karbwang J, Patou C. Standard operating procedures for clinical investigators. TDR/TDP/SOP/99.1.version 1.1 Geneva: WHO; 1999. (Available at http://whqlibdoc.who.int/hq/1999/TDR_TDP_SOP_99.1.pdf Last accessed May 10, 2010)
• 9 Radloff P D, Philipps J, Nkeyi M, Hutchinson D, Kremsner P G. Atovaquone and proguanil for Plasmodium falciparum malaria.  Lancet. 1996;  347 1511-1514
• 10 Willcox M, Olanrewaju O. Guidelines for clinical studies on herbal antimalarials. In: Willcox M, Bodeker G, Rasoanaivo P, eds. Traditional medicinal plants and malaria. Boca Raton, FL: CRC Press; 2004: 321-332
• 11 Mueller M S, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L. Randomised controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria.  Trans Royal Soc Trop Med Hyg. 2004;  98 318-321
• 12 Garcia L S. Malaria and babesiosis. Diagnostic medical parasitology. 4th edn Washington DC: ASM Press; 2001: 159-204
• 13 WHO .Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Available at http://www.who.int/drugresistance/malaria/en/Assessment_malaria_96.pdf Last accessed 10 February 2011
• 14 Sowunmi A, Balogun S T, Gbotosho G O, Happi C T. Effects of amodiaquine, artesunate, and artesunate–amodiaquine on Plasmodium falciparum malaria-associated anaemia in children.  Acta Trop. 2009;  109 55-60
• 15 Vaidya A B, Vaidya R A. Initial human trials with an investigational new drug (Phase 1 and 2): planning and management.  Postgrad Med J. 1981;  27 197-213
• 16 Willcox M L. A clinical trial of “AM”, a Ugandan herbal remedy for malaria.  J Publ Health Med. 1999;  21 318-324
• 17 Willcox M L, Graz B, Falquet J, Sidibé O, Forster M, Diallo D. Argemone mexicana decoction for the treatment of uncomplicated falciparum malaria.  Trans Royal Soc Trop Med Hyg. 2007;  101 1190-1198
• 18 Benoit-Vical F, Valentin A, Dab B, Dakuyo Z, Descamps L, Mallié M. N'Dribala (Cochlospermum planchonii) versus chloroquine for treatment of uncomplicated Plasmodium falciparum malaria.  J Ethnopharmacol. 2003;  89 111-114
• 19 Diallo D, Maïga B, Diakité C, Willcox M. Malarial-5: Development of an antimalarial phytomedicine in Mali. In: Willcox M, Bodeker G, Rasoanaivo P, eds. Traditional medicinal plants and malaria. Boca Raton, FL: CRC Press; 2004: 117-130
• 20 White N J. The assessment of antimalarial drug efficacy.  Trends Parasitol. 2002;  18 458-464
• 21 Bloland P B, Kazembe P N, Oloo A J, Himonga B, Barat L M, Ruebush T K. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa.  Trop Med Int Health. 1998;  3 543-552
• 22 Guiguemdé R T, Gbary R A, Coulibaly S O, Ouedraogo J B. Comment réaliser et interpréter les résultats d'une épreuve de chimiorésistance de P. falciparum chez les sujets malades en zone tropicale.  Cahiers « Santé ». 1996;  3 187-191
• 23 Yeramian P, Meshnick S R, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N, Allen J, Brun R, Kwiek J J, Tidwell R, Looareesuwan S. Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections.  J Infect Dis. 2005;  192 319-322
• 24 Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.  Lancet. 2006;  368 1349-1356
• 25 Osorio L, Gonzalez I, Olliaro P, Taylor W R J. Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.  Malaria J. 2007;  6 25
• 26 Smith T, Hurt N, Teuscher T, Tanner M. Is fever a good sign for clinical malaria in surveys of endemic communities?.  Am J Trop Med Hyg. 1995;  52 306-310
• 27 Luxemburger C, Nosten F, Kyle D E, Kiricharoen L, Chongsuphajaisiddhi T, White N J. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in area of low transmission.  Trans Royal Soc Trop Med Hyg. 1998;  92 45-49
• 28 Missinou M A, Borrmann S, Schindler A, Issifou S, Adegnika A A, Matsiegui P B, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, Kremsner P G. Fosmidomycin for malaria.  Lancet. 2002;  360 1941-1942
• 29 Pieters L, Vlietinck A. Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds?.  J Ethnopharmacol. 2005;  100 57-60
• 30 Xu Y J, Capistrano R, Dhooghe L, Foubert K, Maregesi S, Balde A, Apers S, Pieters L. Herbal medicines and infectious diseases: characterization by LC-SPE-NMR of some medicinal plant extracts used against malaria.  Planta Med. 2011;  77 1139-1148